N/A
Manufactured by Merck Sharp & Dohme LLC
29,953 FDA adverse event reports analyzed
Last updated: 2026-04-14
RALTEGRAVIR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Merck Sharp & Dohme LLC. The most commonly reported adverse reactions for RALTEGRAVIR include DRUG INTERACTION, FOETAL EXPOSURE DURING PREGNANCY, DEPRESSION, ANXIETY, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RALTEGRAVIR.
Out of 16,316 classified reports for RALTEGRAVIR:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 29,953 FDA FAERS reports that mention RALTEGRAVIR. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INTERACTION, FOETAL EXPOSURE DURING PREGNANCY, DEPRESSION, ANXIETY, PAIN, EMOTIONAL DISTRESS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Merck Sharp & Dohme LLC in connection with RALTEGRAVIR. Always verify the specific product and NDC with your pharmacist.